922174-60-5
Chemical Structure
Tertomotide hydrochloride
Synonym(s): GV-1001 hydrochloride
- CAS No.: 922174-60-5
- Formula:C85H147ClN26O21
- Molecular Weight:1904.69
InChIKey: FUJCIASHZNRRQI-DCQNZPEUSA-N
SMILES: O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](N)CCC(O)=O)=O)=O)=O)N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N3[C@@H](CCC3)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.Cl
Biological Activity: Tertomotide hydrochloride (GV-1001 hydrochloride) is a 16-amino acid peptide derived from hTERT, with both cell-penetrating and immunostimulatory activities, and it can cross the blood-brain barrier. Tertomotide hydrochloride binds to STING, HO-1, eHSP70, eHSP90, bradykinin receptor 1, VEGFR-2, NF-κB, p38 MAPK and Smad2. Tertomotide hydrochloride induces type I interferon production, mitochondrial DNA stress and T-cell responses; inhibits HBV replication, angiogenesis, TGF-β signaling pathway, NF-κB activation, endothelial-mesenchymal transition (EndMT) and fibrosis; regulates microglia; and exerts neuroprotective, anti-inflammatory, antioxidant, anti-apoptotic and anti-tumor effects. Tertomotide hydrochloride can be used in research related to hepatitis B virus infection, Alzheimer's disease, non-small cell lung cancer, atherosclerosis and depression[1][2][3][4][5][6][7][8][9][10][11][12].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tertomotide hydrochloride | Tertomotide hydrochloride (GV-1001 hydrochloride) is a 16-amino acid peptide derived from hTERT, with both cell-penetrating and immunostimulatory activities, and it can cross the blood-brain barrier. Tertomotide hydrochloride binds to STING, HO-1, eHSP70, eHSP90, bradykinin receptor 1, VEGFR-2, NF-κB, p38 MAPK and Smad2. Tertomotide hydrochloride induces type I interferon production, mitochondrial DNA stress and T-cell responses; inhibits HBV replication, angiogenesis, TGF-β signaling pathway, NF-κB activation, endothelial-mesenchymal transition (EndMT) and fibrosis; regulates microglia; and exerts neuroprotective, anti-inflammatory, antioxidant, anti-apoptotic and anti-tumor effects. Tertomotide hydrochloride can be used in research related to hepatitis B virus infection, Alzheimer's disease, non-small cell lung cancer, atherosclerosis and depression. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Choi YM, et al. A Telomerase-Derived Peptide Exerts an Anti-Hepatitis B Virus Effect via Mitochondrial DNA Stress-Dependent Type I Interferon Production. Front Immunol. 2020 May 21;11:652. [Content Brief]
- [2]. Lee Y, et al. A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease. Experimental & molecular medicine. 2026 Jun;58(6):1789-1805.
- [3]. Kim JH, et al. A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: Regulation of VEGF/VEGFR-2 signaling pathways. Translational oncology. 2022 Dec;26:101546. [Content Brief]
- [4]. Chen W, et al. GV1001, hTERT Peptide Fragment, Prevents Doxorubicin-Induced Endothelial-to-Mesenchymal Transition in Human Endothelial Cells and Atherosclerosis in Mice. Cells. 2025 Jan 10;14(2):98. [Content Brief]
- [5]. Choi J, et al. The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production. Immune network. 2015 Dec;15(6):291-303. [Content Brief]
- [6]. Chen W, et al. hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF‑β signaling. International journal of molecular medicine. 2018 Jun;41(6):3211-3220.
- [7]. Koh SH, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimer's research & therapy. 2021 Mar 26;13(1):66. [Content Brief]
- [8]. Kyte JA, et al. Cancer vaccination with telomerase peptide GV1001. Expert opinion on investigational drugs. 2009 May;18(5):687-94. [Content Brief]
- [9]. Park HH, et al. Novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiology of aging. 2014 Jun;35(6):1255-74. [Content Brief]
- [10]. Huang YF, et al. Single-cell multi-omic integration analysis prioritizes druggable genes and reveals cell-type-specific causal effects in glioblastomagenesis. Journal of translational medicine. 2026 May 23;24(1):940. [Content Brief]
- [11]. Lee EK, et al. A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model. Translational research : the journal of laboratory and clinical medicine. 2020 Feb;216:30-42.
- [12]. Kim D, et al. Anti-depressant effects of a human telomerase-derived peptide GV1001 in an animal model of chronic restraint stress. Behavioural brain research. 2025 Oct 02;494:115724.
